Retatrutide's Potential FDA Approval for Weight Loss by 2026 | Retatrutide News

Retatrutide, a GLP-1 agonist from Eli Lilly, is expected to receive FDA approval for weight loss by 2026. This development underscores the growing inter...
Market News · October 17, 2026